CN102088994B - 基于吲哚胺2，3-双加氧酶的免疫疗法 - Google Patents

基于吲哚胺2，3-双加氧酶的免疫疗法 Download PDF

Info

Publication number
CN102088994B
CN102088994B CN200980122844.0A CN200980122844A CN102088994B CN 102088994 B CN102088994 B CN 102088994B CN 200980122844 A CN200980122844 A CN 200980122844A CN 102088994 B CN102088994 B CN 102088994B
Authority
CN
China
Prior art keywords
cells
ido
cancer
vaccine composition
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980122844.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102088994A (zh
Inventor
梅斯·哈尔德·安德森
珀·托尔·斯特拉藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
Herlev Hospital Region Hovedstaden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Herlev Hospital Region Hovedstaden filed Critical Herlev Hospital Region Hovedstaden
Priority to CN201410247727.XA priority Critical patent/CN104056261B/zh
Publication of CN102088994A publication Critical patent/CN102088994A/zh
Application granted granted Critical
Publication of CN102088994B publication Critical patent/CN102088994B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN200980122844.0A 2008-04-17 2009-04-17 基于吲哚胺2，3-双加氧酶的免疫疗法 Active CN102088994B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410247727.XA CN104056261B (zh) 2008-04-17 2009-04-17 基于吲哚胺2,3-双加氧酶的免疫疗法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200800565 2008-04-17
DKPA200800565 2008-04-17
PCT/DK2009/000095 WO2009143843A1 (en) 2008-04-17 2009-04-17 Indoleamine 2, 3-dioxygenase based immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410247727.XA Division CN104056261B (zh) 2008-04-17 2009-04-17 基于吲哚胺2,3-双加氧酶的免疫疗法

Publications (2)

Publication Number Publication Date
CN102088994A CN102088994A (zh) 2011-06-08
CN102088994B true CN102088994B (zh) 2014-06-25

Family

ID=40873320

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980122844.0A Active CN102088994B (zh) 2008-04-17 2009-04-17 基于吲哚胺2，3-双加氧酶的免疫疗法
CN201410247727.XA Active CN104056261B (zh) 2008-04-17 2009-04-17 基于吲哚胺2,3-双加氧酶的免疫疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410247727.XA Active CN104056261B (zh) 2008-04-17 2009-04-17 基于吲哚胺2,3-双加氧酶的免疫疗法

Country Status (20)

Country Link
US (7) US9433666B2 (https=)
EP (3) EP3320912B1 (https=)
JP (2) JP2011520783A (https=)
CN (2) CN102088994B (https=)
AU (1) AU2009253539B2 (https=)
CA (1) CA2721150C (https=)
CY (2) CY1120352T1 (https=)
DK (2) DK3320912T3 (https=)
ES (2) ES2870596T3 (https=)
HR (2) HRP20180282T1 (https=)
HU (2) HUE037973T2 (https=)
IL (1) IL208781A (https=)
LT (2) LT2280721T (https=)
NO (1) NO2280721T3 (https=)
NZ (1) NZ588757A (https=)
PL (2) PL3320912T3 (https=)
PT (2) PT2280721T (https=)
SI (2) SI3320912T1 (https=)
WO (1) WO2009143843A1 (https=)
ZA (1) ZA201008056B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3320912B1 (en) 2008-04-17 2021-03-31 IO BIOTECH ApS Indoleamine 2, 3-dioxygenase based immunotherapy
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
JP6605591B2 (ja) * 2014-05-29 2019-11-13 スプリング バイオサイエンス コーポレーション 抗インドールアミン２，３−ジオキシゲナーゼ１抗体及びその診断的使用
SI3193917T1 (sl) * 2014-09-17 2022-02-28 Io Biotech Aps Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce
CN106148276A (zh) * 2015-04-16 2016-11-23 中国科学院上海生命科学研究院 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
IL255722B2 (en) 2015-06-29 2024-05-01 Ose Immunotherapeutics A method for inducing an early memory response with an anticancer vaccine of short peptides
US11298413B2 (en) 2015-09-16 2022-04-12 Io Biotech Aps Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof
HRP20240052T1 (hr) * 2016-03-04 2024-03-29 Io Biotech Aps Kombinirana terapija protiv raka
EP3468585A2 (en) 2016-06-10 2019-04-17 IO Biotech APS Calr and jak2 vaccine compositions
AU2017340387A1 (en) * 2016-10-04 2019-05-02 University Of Florida Research Foundation, Inc. Targeted effector proteins and uses thereof
CN110249056A (zh) * 2016-10-14 2019-09-17 苏黎世大学 用于前列腺癌诊断及预后的吲哚胺-2,3-双加氧酶检测
RU2769474C2 (ru) * 2017-01-20 2022-04-01 Атара Байотерапьютикс, Инк. Способы лечения рассеянного склероза с использованием аутологичных т-клеток
US10738100B2 (en) 2017-01-27 2020-08-11 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SI3573647T1 (sl) 2017-01-27 2023-07-31 Immatics Biotechnologies Gmbh Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka
WO2018138257A1 (en) * 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof
NZ765655A (en) 2017-11-27 2026-01-30 Ose Immunotherapeutics Improved treatment of cancer
US12577282B2 (en) 2019-02-28 2026-03-17 University Of Florida Research Foundation, Incorporated Galectin-1/ galectin-3 chimeras and multivalent proteins
CN109758467B (zh) * 2019-03-08 2020-12-25 中国农业科学院兰州兽医研究所 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用
AU2020371562A1 (en) * 2019-10-23 2022-06-09 The Council Of The Queensland Institute Of Medical Research Adoptive immunotherapy
WO2022006424A2 (en) 2020-07-02 2022-01-06 The Regents Of The University Of Californa Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways
CN112881269A (zh) * 2021-02-23 2021-06-01 浙江正熙生物技术股份有限公司 一种流式荧光检测试剂的质量检测方法
GB202103673D0 (en) 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
CN114657158B (zh) * 2022-05-25 2022-10-21 深圳吉诺因生物科技有限公司 Ido1相关疫苗及其应用
US20240238384A1 (en) * 2023-01-17 2024-07-18 Regeneron Pharmaceuticals, Inc. Treatment Of B27-Negative Uveitis With Inositol Polyphosphate Multikinase (IPMK) Therapeutic Agents Or Indoleamine 2,3-dioxygenase 2 (IDO2) Agonists
EP4669344A2 (en) * 2023-02-21 2025-12-31 Salvitus, Inc. Recombinant phages, probiotic vaccines and therapeutic agents, combined compositions and methods of use
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine
WO2025189043A2 (en) * 2024-03-07 2025-09-12 Salvitus, Inc. Oral vaccine compositions and related methods
WO2025242193A1 (zh) * 2024-05-24 2025-11-27 重庆医科大学 博来霉素作为免疫增强剂的用途
WO2026008025A1 (en) * 2024-07-03 2026-01-08 Everest Medicines (China) Co., Ltd. Ido1 cancer vaccines and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1194006A (zh) * 1995-06-20 1998-09-23 麦克公司 利用双加氧酶生物转化与化学步骤相结合的茚向无任何立体异构体的(is)－氨基－(2r)－茚满醇的转化
CN1223688A (zh) * 1996-06-27 1999-07-21 纳幕尔杜邦公司 对羟基苯丙酮酸双加氧酶的植物基因
CN1270636A (zh) * 1997-07-14 2000-10-18 Basf公司 编码羟苯基丙酮酸双加氧酶的dna序列及其于植物中的超量生产

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
CN1221349A (zh) 1996-06-12 1999-06-30 郭亚军 细胞疫苗、免疫治疗以及它们的制备方法
US6451840B1 (en) 1997-12-05 2002-09-17 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by tryptophan
AU4697600A (en) 1999-05-03 2000-11-17 Ludwig Institute For Cancer Research Methods for increasing t cell proliferation
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス， インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
AU2002258518A1 (en) 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20030148316A1 (en) 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US20060292618A1 (en) 2002-04-12 2006-12-28 Mellor Andrew L Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
CA2483451C (en) 2002-04-12 2014-07-29 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004053075A2 (en) 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
RU2005122033A (ru) 2002-12-13 2006-01-27 Митра Медикал Текнолоджи Аб (Se) Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
US7714139B2 (en) 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
US20050186289A1 (en) * 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
WO2005036127A2 (en) 2003-10-02 2005-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying target cell cytolytic lymphocytes in a sample
WO2006005185A1 (en) * 2004-07-13 2006-01-19 The University Of British Columbia Indoleamine 2,3-dioxygenase (ido) inhibitors
US20060110371A1 (en) 2004-11-23 2006-05-25 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
ES2523172T3 (es) 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
KR101536239B1 (ko) * 2005-09-23 2015-07-13 셀레릭스, 에스.엘. 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도
WO2007095050A2 (en) 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
WO2007115068A2 (en) 2006-03-30 2007-10-11 Indiana University Research And Technology Corporation Genetic variants in the indoleamine 2,3-dioxygenase gene
WO2008143668A2 (en) * 2006-05-18 2008-11-27 Lankenau Institute For Medical Research Indoleamine-2, 3-dioxygenase-2
US8507434B2 (en) * 2007-01-03 2013-08-13 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
EP3320912B1 (en) 2008-04-17 2021-03-31 IO BIOTECH ApS Indoleamine 2, 3-dioxygenase based immunotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1194006A (zh) * 1995-06-20 1998-09-23 麦克公司 利用双加氧酶生物转化与化学步骤相结合的茚向无任何立体异构体的(is)－氨基－(2r)－茚满醇的转化
CN1223688A (zh) * 1996-06-27 1999-07-21 纳幕尔杜邦公司 对羟基苯丙酮酸双加氧酶的植物基因
CN1270636A (zh) * 1997-07-14 2000-10-18 Basf公司 编码羟苯基丙酮酸双加氧酶的dna序列及其于植物中的超量生产

Also Published As

Publication number Publication date
HUE037973T2 (hu) 2018-09-28
CY1120352T1 (el) 2019-07-10
HRP20210766T1 (hr) 2021-07-23
US11324813B2 (en) 2022-05-10
CA2721150A1 (en) 2009-12-03
US9433666B2 (en) 2016-09-06
CN104056261A (zh) 2014-09-24
CN102088994A (zh) 2011-06-08
ZA201008056B (en) 2011-07-27
EP3320912A1 (en) 2018-05-16
US20190201512A1 (en) 2019-07-04
JP6016966B2 (ja) 2016-10-26
US20220249641A1 (en) 2022-08-11
EP2280721B1 (en) 2017-11-15
US20250319159A1 (en) 2025-10-16
SI3320912T1 (sl) 2021-08-31
LT3320912T (lt) 2021-07-12
WO2009143843A1 (en) 2009-12-03
JP2015129182A (ja) 2015-07-16
US20230233657A1 (en) 2023-07-27
IL208781A (en) 2017-09-28
EP3320912B1 (en) 2021-03-31
HRP20180282T1 (hr) 2018-03-23
ES2657963T3 (es) 2018-03-07
PT2280721T (pt) 2018-02-16
US12233103B2 (en) 2025-02-25
US20220202922A1 (en) 2022-06-30
PL2280721T3 (pl) 2018-04-30
DK2280721T3 (da) 2018-01-29
US20110318372A1 (en) 2011-12-29
ES2870596T3 (es) 2021-10-27
CY1124279T1 (el) 2022-07-22
HUE055338T2 (hu) 2021-11-29
US20170049868A1 (en) 2017-02-23
DK3320912T3 (da) 2021-05-31
AU2009253539A1 (en) 2009-12-03
CA2721150C (en) 2017-09-26
US11648302B2 (en) 2023-05-16
EP2280721A1 (en) 2011-02-09
PL3320912T3 (pl) 2021-10-25
NO2280721T3 (https=) 2018-04-14
LT2280721T (lt) 2018-02-12
IL208781A0 (en) 2010-12-30
CN104056261B (zh) 2017-01-11
PT3320912T (pt) 2021-05-24
AU2009253539B2 (en) 2014-03-20
NZ588757A (en) 2012-05-25
JP2011520783A (ja) 2011-07-21
SI2280721T1 (en) 2018-02-28
EP3915570A1 (en) 2021-12-01
US10258678B2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
US12233103B2 (en) Indoleamine 2,3-dioxygenase based immunotherapy
JP6259763B2 (ja) Ｐｄ−ｌ１に基づく免疫療法
US11878053B2 (en) Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
CN108472345B (zh) 包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物
HK1247114A1 (en) Indoleamine 2, 3-dioxygenase based immunotherapy
HK1247114B (en) Indoleamine 2, 3-dioxygenase based immunotherapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20170210

Address after: Copenhagen

Patentee after: IO Biotech Corp

Address before: Denmark Herlev

Patentee before: Hvidovre Hospital